title: Where does radioimmunotherapy fit in the management of breast cancer?
abstract: Breast cancer is one of the most commonly diagnosed malignancies and is the main cause of death in women aged 40-49 years. Metastatic breast cancer is a heterogeneous disease that has a variety of different clinical presentations, ranging from solitary metastatic lesion to diffuse and multiple organ involvement. The biological heterogeneity of metastatic breast cancer has led to its unpredictable clinical behavior. One of the major challenges, therefore, is to identify predictive and prognostic models facilitating the selection of patients who can benefit from more aggressive and potentially curative options. This article provides an overview of the current management of metastatic breast cancer with focused emphasis on radioimmunotherapy.
authors.affiliation: Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT 06520-8042, USA. indukala.doddamane@yale.edu
authors.forename: Indu
authors.initials: I
authors.lastname: Doddamane
authors.forename: Reni
authors.initials: R
authors.lastname: Butler
authors.forename: Ami
authors.initials: A
authors.lastname: Jhaveri
authors.forename: Gina G
authors.initials: GG
authors.lastname: Chung
authors.forename: David
authors.initials: D
authors.lastname: Cheng
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D016499:Radioimmunotherapy / Q000379:methods* / Q000639:trends; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000922:Immunotoxins